Skip to main navigation

About Us

Our Company

Overview Management Team Board of Directors Scientific Advisory Board Partners & Collaborations

Contact

Our Pipeline

Pipeline

Overview Azenosertib

Clinical Trials

Our Approach

Integrated Discovery Engine

Our advanced approach to efficiently identifying and developing novel oncology therapies.

Supporting Publications

Investors & Media

Investor Home

News & Events

Press Releases Events & Presentations

Stock Information

Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage

Financials & Filings

SEC Filings

Corporate Governance

Documents & Charters Management Team Board of Directors Scientific Advisory Committee Committee Composition

Investor Resources

Investor FAQs Investor Contact Email Alerts

Careers

Working at Zentalis

Be part of a vibrant team committed to our common goal: to better the lives of patients impacted by cancer.

Job Opportunities

Investors & Media

Press Releases

Investor Relations Menu

Investor Home

News & Events

Press Releases Events & Presentations

Stock Information

Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage

Financials & Filings

SEC Filings

Corporate Governance

Documents & Charters Management Team Board of Directors Scientific Advisory Board Committee Composition

Investor Resources

Investor FAQs Investor Contact Email Alerts

Contact

Elizabeth Pingpank Hickin
Vice President, Investor Relations
ehickin@zentalis.com

Year

Mar 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 28, 2024

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 27, 2024

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

Feb 13, 2024

Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference

Feb 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 25, 2024

Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments

Jan 08, 2024

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

Jan 02, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 28 of 28

Science Center

10275 Science Center Drive
Suite 200
San Diego, CA 92121

About Us

Our Company Management Team Board of Directors Scientific Advisory Board Partners & Collaborations Contact

Our Pipeline

Overview Azenosertib Clinical Trials

Our Approach

Integrated Discovery Engine Supporting Publications

Investors & Media

News & Events Stock Information Financials & Filings Corporate Governance Investor Resources

Privacy Policy

Terms of Use

Expanded Access Policy

Site Map

Careers